Literature DB >> 32777309

Why it is crucial to maintain oral care for patients undergoing head and neck radiotherapy during the COVID-19 pandemic.

B A Rocha1, P A Mendes2, L M C Lima3, M C Lima3, P E A Souza2, S M C Grossmann2, G R Souto2, M C R Horta2.   

Abstract

Entities:  

Year:  2020        PMID: 32777309      PMCID: PMC7411420          DOI: 10.1016/j.jormas.2020.07.009

Source DB:  PubMed          Journal:  J Stomatol Oral Maxillofac Surg        ISSN: 2468-7855            Impact factor:   1.569


× No keyword cloud information.
Dear Editor, Patients with head and neck cancer (HNC) require care based upon transdisciplinary approaches, which alone allow both treating oncological disease and responding to the adverse effects of anti-cancer therapies that can interrupt treatment and, in turn, threaten patients’ survival [1]. For patients with HNC, radiotherapy (RT) is an important therapeutic modality. Although technological advances have made it possible to administer high doses of radiation with greater precision and target tissue localization, some toxic radioinduced oral effects remain prevalent (Table 1 ) [2]. Such effects can cause oral complications during RT itself (i.e., acute complications) or a few months, even years, after RT (i.e., chronic complications) [1]. In prevent those complications, the prophylaxis and management of RT's potentially toxic effects require dental teams specialized in caring for patients with cancer, which can, in turn, help to improve the quality of cancer care.
Table 1

Radioinduced oral complications [1], [2], [3].

Radioinduced oral complicationsPrevalence
AcuteMucositis>90%
Fungal infections (most commonly oral candidiasis)37.4% (during RT)
Xerostomia (dry mouth feeling)Conventional RT
Pre-RT: 10%
During RT: 81%
IMRT
Pre-RT: 12%
During RT: 100%
DysgeusiaRT: 66.5%



ChronicTrismusConventional RT: 25.4%
IMRT: 5%
XerostomiaConventional RT
>2 years post-RT: 91%
IMRT
>2 years post-RT: 68%
Osteoradionecrosis (more cases affect the mandible than the maxilla)Conventional RT: 7.4%
IMRT: 5.2%
Brachytherapy: 5.3%
Dental cariesPost-RT: 24%

Note: RT = radiotherapy; IMRT = intensity-modulated radiotherapy.

Radioinduced oral complications [1], [2], [3]. Note: RT = radiotherapy; IMRT = intensity-modulated radiotherapy. Such pre-emptive action needs to begin in the pre-RT period. At that stage, consultation with the patient should be performed with the aim of diagnosing and treating existing oral diseases, as well as planning preventative measures for possible complications (e.g., mucositis) [1], [3]. Indeed, patients who have not received such consultation have demonstrated a higher risk of complications [1]. Therefore, in the pre-RT period, two particular procedures should be performed. First, the adequacy of the oral environment (e.g., restorations and extractions of teeth with questionable prognosis) should be examined, and infectious foci as well as traumatic and retentive factors should be eliminated. Second, guidance on the importance of strict oral hygiene and oral care to be followed during RT should be provided. During RT itself, the patient needs to be routinely examined by the dental team. In response to the appearance of any toxic oral effects, specific therapeutic measures have to be taken to relieve pain, maintain oral food intake, and prevent the temporary or even permanent interruption of RT. In the post-RT period, preventative and curative care for later effects needs to be provided, along with rehabilitative care. Thereafter, because the risk of complications persists throughout life [1], patient follow-up needs to become routine. The current COVID-19 pandemic, caused by SARS-CoV-2, has greatly impacted the performance of transdisciplinary teams in cancer treatment centers. Although the treatment of most patients with HNC remains a top priority amid the pandemic, as evidenced in a joint recommendation by the American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) [5], the performance of dental oncologists has been affected [6], [7]. In particular, the high risk of viral infection faced by dental teams and patients, chiefly via fluids and aerosols for the oral cavity used in certain dental treatments [6], [8], has prompted dental services to postpone or discontinue appointments [9]. Nevertheless, the adequacy of oral care that accommodates infection control measures currently recommended by competent entities [10] can allow dental care for patients with cancer to be maintained. For such care to continue, however, dental teams need be vigilant and provide safe environments for themselves and their patients [8], [10]. To that purpose, personalized treatment plans for patients and partnerships with radiation oncologists are essential [9]. Prescreening over the phone can reveal symptoms possibly associated with COVID-19 and may justify postponing in-person consultation. If such consultation is deemed safe, then general safety measures need to include assessing the patient's body temperature, practicing frequent hand hygiene, disinfecting equipment and clinical surfaces, and using personal protective equipment consisting of masks (i.e., N95 or FFP2), disposable medical aprons, gloves, glasses, and face shields [8], [10]. Prior to procedures, chlorhexidine mouthwashes can help to reduce the viral load of the SARS-CoV-2 in the saliva [4]. In oral care before, during, and after RT, droplet- and aerosol-generating procedures should be avoided, and extraoral imaging exams (e.g., panoramic radiography and cone beam computed tomography) should be used instead of intraoral radiographs [8]. In the pre-RT period, tooth extractions should be performed atraumatically and using resorbable sutures [9]. Last, the use of handpieces, rotating instruments, and triple syringes should be reduced; atraumatic restorative procedures or the chemical–mechanical removal of carious lesions are promising alternatives [8], [9]. During RT, in response to the appearance of unwanted effects, antibiotic, anti-inflammatory, analgesic, and topical medications (e.g., artificial saliva, mouthwash with saline, and bicarbonated water) should be prescribed [3], [9]. At the same time, mucositis may appear in association with oral pain and odynophagia. Due to the intensity of symptoms, some cases may require RT to be suspended and/or the use of enteral and parenteral nutrition. Among possible therapeutic measures for mucositis, photobiomodulation therapy (i.e., laser therapy) stands out, given its antalgic, reparative, and anti-inflammatory effects [3], with no production of aerosols. Considering the need to reduce patients’ visits to clinics [6], the use of remote patient support via virtual visits can facilitate continued contact with and immediate clinical attention when needed [7]. In view of the need to continually update guidelines for the prevention of COVID-19, updated information can be obtained from national and international bodies and organizations [10], including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Altogether, we believe that maintaining oral care for patients with HNC in RT is possible, as long as biosafety guidelines for preventing COVID-19 are followed and respected [10]. The role of the dental oncologist aims, above all, to contribute to the quality of life of cancer patients. As in our service at the Radialis Santa Casa Radiotherapy Clinic (Montes Claros, Brazil), those measures can positively impact the quality of patient care in RT centers around the world.

Declarations of interest

None declared.
  2 in total

1.  Importance of the treatment of patients with lip and palate cleft, especially during the COVID-19 pandemic.

Authors:  Leonardo Pereira Alexandre; Leticia Nava Lopes Cançado; Henrique Pretti; Elizabeth Maria Bastos Lages; Yasmim Caroline Furtado de Lima; Maria Inês Mantuani Pascoaloti; Soraya de Mattos Camargo Grossmann
Journal:  Oral Surg       Date:  2020-12-23

Review 2.  Covid-19 and radiotherapy: a systematic review after 2 years of pandemic.

Authors:  Antonio Piras; Valeria Venuti; Andrea D'Aviero; Davide Cusumano; Stefano Pergolizzi; Antonino Daidone; Luca Boldrini
Journal:  Clin Transl Imaging       Date:  2022-07-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.